Delavirdine: Clinical Trials

6 completed, 1 terminated, 1 withdrawn. 8 Phase 2, 1 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	8	Completed 6, Terminated 1, Withdrawn 1
Phase 3	1	Completed 1

Follow Delavirdine: new trials by email Literature Review of Delavirdine trials Research Report on Delavirdine

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Clinical Trial of CNS-targeted HAART (CIT2) FDA Approved Antiretroviral Therapy (see list below) - HIV Infections	Phase 2 / Phase 3	Completed	University of California, San Diego	59	2007-03-01	2014-04-23
Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir Tipranavir (TPV), Ritonavir (RTV), Delavirdine (DLV) - HIV Infections	Phase 2	Completed	Boehringer Ingelheim	18	1999-03-01	2014-09-25
A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy Delavirdine mesylate, Zidovudine, Didanosine - HIV Infections	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	471		2021-11-04
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors Emivirine, Hydroxyurea, Delavirdine mesylate - HIV Infections	Phase 2	Terminated	Bristol-Myers Squibb	25		2008-08-14
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies Delavirdine mesylate - HIV Infections	Phase 2	Completed	Pharmacia and Upjohn	24		2005-06-24
A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients Lamivudine/Zidovudine, Nelfinavir mesylate, Saquinavir - HIV Infections	Phase 2	Withdrawn	National Institute of Allergy and Infectious Diseases (NIAID)			2015-03-09
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects Indinavir sulfate, Delavirdine mesylate, Lamivudine - HIV Infections	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	300		2013-07-29
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 Ritonavir, Saquinavir, Delavirdine mesylate - HIV Infections	Phase 2	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	34		2021-11-04

Conditions studied

HIV Infections (8)  ·  AIDS Dementia Complex (1)  ·  AIDS-Related Complex (1)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Cognitive Dysfunction (1)  ·  Hypersensitivity, Delayed (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (4)  ·  Boehringer Ingelheim (1)  ·  Bristol-Myers Squibb (1)  ·  Pharmacia and Upjohn (1)  ·  University of California, San Diego (1)

Countries

United States (7)  ·  Puerto Rico (3)

Top investigators

Bartlett J (1)  ·  Fischl M (1)  ·  Fischl MA (1)  ·  Friedland G (1)  ·  Harold Kessler (1)  ·  Hernan Valdez (1)  ·  Johnson V (1)  ·  Kimberly Smith (1)  ·  Kuritzkes D (1)  ·  Michael Lederman (1)  ·  Pollard R (1)  ·  Ronald J Ellis, MD, PhD (1)

Results publications

PMID 24352352

NIH funding

R01MH058076 (1)